RxDoctor Payments Data

Christina Warren

Family · West Des Moines, IANPI 1730406356

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 28.8% of the total. Reporting peaked in 2023 at $1,357 and has fallen 51.3% since, to $661 in 2025. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,030in general payments, 2019–2025

Across 182 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$606
  • Novartis$570
  • E.r. Squibb & Sons, L.L.C.$368
  • Pfizer$235
  • Sun Pharmaceutical Industries Inc.$196
  • plus $896 from 11 others

What the payments were for

  • Food & beverage$3,89297%
  • Education$1393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,030 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$161,065
Medicare patients
521
Services billed
3,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab11$94,619
Dupixent PenDupilumab12$44,852
Clobetasol Propionate71$4,462
Metronidazole27$2,824
Tretinoin16$1,330
Ketoconazole94$1,207
Fluocinonide23$1,116
Desonide11$577
Triamcinolone Acetonide56$550
Hydrocortisone31$223
Selenium Sulfide15$184
ValacyclovirValacyclovir Hcl35$170
Fluconazole13$155
Imiquimod12$145
Doxycycline Hyclate12$136

Paid to pharmacies, not to this prescriber.

Other family in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →